News
MOLN
3.990
-5.23%
-0.220
Weekly Report: what happened at MOLN last week (0914-0918)?
Weekly Report · 1d ago
Weekly Report: what happened at MOLN last week (0907-0911)?
Weekly Report · 09/14 09:53
Weekly Report: what happened at MOLN last week (0831-0904)?
Weekly Report · 09/07 09:49
Clear Street transfers coverage on Molecular Partners, keeps Buy rating
TipRanks · 09/04 20:15
Weekly Report: what happened at MOLN last week (0824-0828)?
Weekly Report · 08/31 09:54
Molecular Partners: Pipeline Momentum and Early Safety Data Support Unchanged $12 Price Target and Buy Rating
TipRanks · 08/25 20:15
Molecular Partners GAAP EPS of -CHF0.70
Seeking Alpha · 08/25 11:54
Molecular Partners Advances DLL3 Radio-DARPin MP0712 and Expands Alpha Therapy Pipeline on Solid H1 2026 Cash Base
TipRanks · 08/25 10:27
Molecular Partners Reports H1 2026 Results, Advances DLL3 Radiotherapy MP0712
NASDAQ · 08/25 10:18
Molecular Partners Q2 EPS $(0.89) Misses $(0.45) Estimate
Benzinga · 08/25 10:15
Molecular Partners Reports H1 2026 Financial Results and Corporate Highlights: DLL3 Radiotherapy MP0712 Successfully Advancing to Higher Dose Level in Phase 1/2a Study
Barchart · 08/25 00:00
Weekly Report: what happened at MOLN last week (0817-0821)?
Weekly Report · 08/24 09:54
Weekly Report: what happened at MOLN last week (0810-0814)?
Weekly Report · 08/17 09:55
Weekly Report: what happened at MOLN last week (0803-0807)?
Weekly Report · 08/10 09:51
Weekly Report: what happened at MOLN last week (0727-0731)?
Weekly Report · 08/03 09:51
Weekly Report: what happened at MOLN last week (0720-0724)?
Weekly Report · 07/27 09:54
Molecular Partners Starts Phase 2 TACTIC Trial of MP0317 in Front-Line Cholangiocarcinoma
TipRanks · 07/20 12:48
Weekly Report: what happened at MOLN last week (0713-0717)?
Weekly Report · 07/20 09:51
Molecular Partners doses first patients in MP0317 combination study
TipRanks · 07/16 09:41
Molecular Partners Advanced Phase 2 Study Of MP0317 In Cholangiocarcinoma; Stock Up
NASDAQ · 07/16 07:38
More
Webull provides a variety of real-time MOLN stock news. You can receive the latest news about MOLECULAR PARTNERS AG through multiple platforms. This information may help you make smarter investment decisions.
About MOLN
Molecular Partners AG is a Switzerland-based clinical-stage biotech company developing DARPin (Designed Ankyrin Repeat Proteins) a new class of custom-built protein therapeutics based on natural binding proteins that open a new dimension of multi-functionality and multi-target specificity in drug design. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.